Veklury gets to be first COVID-19 therapy OKed in Australia
Clocking up another approval for the repurposed anti-viral, Australia’s Therapeutic Goods Administration (TGA) has granted provisional approval to US biotech major Gilead Sciences’ (Nasdaq: GILD) Veklury (remdesivir) as the first treatment option for COVID-19 in the country.
Veklury has received provisional approval for use in adults and adolescent patients with severe COVID-19 symptoms who have been hospitalized.
Remdesivir is the most promising treatment option so far to reduce hospitalization time for those suffering from severe coronavirus infections. Also, though announced after the TGA completed its regulatory review of the product, Gilead recently revealed new data showing that Veklury also significantly reduced the risk of death in COVID-19 patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze